[1]CurrentPatentAssignee:ROCHEHOLDINGAG-US2010/75948,2010,A1Locationinpatent:Page/Pagecolumn153
[1]CurrentPatentAssignee:PFIZERINC-US2010/196321,2010,A1Locationinpatent:Page/Pagecolumn35
[1]Kazmierski,WieslawM.;Hamatake,Robert;Duan,Maosheng;Wright,LoisL.;Smith,GaryK.;Jarvest,RichardL.;Ji,Jing-Jing;Cooper,JoelP.;Tallant,MatthewD.;Crosby,RenaeM.;Creech,Katrina;Wang,Amy;Li,Xianfeng;Zhang,Suoming;Zhang,Yong-Kang;Liu,Yang;Ding,CharlesZ.;Zhou,Yasheen;Plattner,JacobJ.;Baker,StephenJ.;Bu,Wei;Liu,Liang[JournalofMedicinalChemistry,2012,vol.55,#7,p.3021-3026]
[1]Bogolubsky,AndreyV.;Moroz,YuriiS.;Mykhailiuk,PavelK.;Granat,DmitryS.;Pipko,SergeyE.;Konovets,AnzhelikaI.;Doroschuk,Roman;Tolmachev,Andrey[ACSCombinatorialScience,2014,vol.16,#6,p.303-308]
[1]CurrentPatentAssignee:CHINAPETROCHEMICALCORPORATION-CN104557610,2018,BLocationinpatent:Paragraph0138;0139;0140;0151;0152
Title: Structural analysis of 2-piperidin-4-yl-actamide derivatives for hERG blocking and MCH R1 antagonistic activities.
Journal: Current drug discovery technologies 20120301
Title: Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition.
Journal: Bioorganic & medicinal chemistry letters 20090801